Have you or has someone in your family been diagnosed with Multiple Primary Breast Cancer or Triple Negative Breast Cancer (TNBC)?
Did you know that 1 in 5 people diagnosed with breast cancer have the KRAS-variant?
The KRAS-variant an inherited gene mutation that provides powerful, life-saving information about an individual’s additional cancer risk, as well as information on how they will respond to specific cancer treatments.
If you or your family member has been diagnosed with multiple primary breast cancer or triple negative breast cancer, you are eligible for our studies as well as for KRAS-variant testing. We hope you will take the eligibility survey.
What we know about the KRAS-variant:
- Found in 6-10% of the population, but up to 25% of cancer patients.
- Breast cancer is triggered by estrogen withdrawal, and KRAS-variant patients have an increase risk of both triple negative breast cancer as well as multiple primary breast cancer.
- Predicts sensitivity and resistance to several standard-of-care cancer treatments/therapies.
- Explains the genetic cause of cancer for over 50% of Hereditary Breast and Ovarian Cancer (HBOC) families with no other known genetic markers.
- Associated primarily with post-menopausal ovarian cancer, enabling the opportunity for cancer prevention through informed decision making about ophorectomy (ovarian removal) at menopause.
The KRAS-variant is a recently discovered, novel, inherited genetic marker associated with cancer. The latest research indicates the KRAS-variant shows great potential to guide disease prevention and management across cancer types through its unique interactions with hormones and cancer therapies.
TAKE THE ELIGIBILITY SURVEY
We encourage you to see if you are eligible to join a MiraKind study to help us discover meaningful ways to better treat patients with genetic mutations. If you would like to join a study, please click the button below. You will be able to choose to get your KRAS-variant results at a discounted cost ($195) through the study. If you would prefer to directly order KRAS-variant testing at cost ($295) without joining a study, please follow this link.
MiraKind’s pipeline of planned and ongoing research studies are designed to protect the health of individuals with the KRAS-variant and to help answer the most pressing questions about cancer.
Research questions include:
- What are the best cancer management strategies for KRAS-variant cancer patients? Including, which anti-estrogen is safest?
- What environmental factors, hormone exposures, medicines, or other lifestyle factors can influence cancer risk for individuals with the KRAS-variant?
- How do individuals with the KRAS-variant respond differently to factors like hormone replacement therapy, birth control, or IVF?
- How can cancer survivors who are positive for the KRAS-variant protect themselves from secondary cancers?
- How can we prevent cancers associated with the KRAS-variant for family members who are positive but have never been diagnosed with cancer?